Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

Rising breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously immunized individuals have raised concerns for the need for a booster vaccine dose to combat waning antibody levels and new variants. Here we report the results of the open-label, non-randomi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2022-05, Vol.28 (5), p.1042-1049
Hauptverfasser:	Chu, Laurence, Vrbicky, Keith, Montefiori, David, Huang, Wenmei, Nestorova, Biliana, Chang, Ying, Carfi, Andrea, Edwards, Darin K., Oestreicher, Judy, Legault, Holly, Dutko, Frank J., Girard, Bethany, Pajon, Rolando, Miller, Jacqueline M., Das, Rituparna, Leav, Brett, McPhee, Roderick
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/590/2293 631/326/590/2293 Adverse events Antibodies Biomedical and Life Sciences Biomedicine Cancer Research Confidence intervals Coronaviruses COVID-19 COVID-19 vaccines Enzyme-linked immunosorbent assay IgG antibody Immune response Immune system Immunization Immunogenicity Immunoglobulin G Immunological memory Infectious Diseases Injection Metabolic Diseases Molecular Medicine mRNA Neurosciences Neutralizing Respiratory diseases Severe acute respiratory syndrome coronavirus 2 Vaccination Vaccine efficacy Vaccines Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!